{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:05:19Z","timestamp":1753891519409,"version":"3.41.2"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Ashitaba seems to improve glucose intolerance and decrease triglyceride (TG) and total cholesterol (TC), which contribute to the development of non-alcoholic fatty liver disease (NAFLD). However, it remains to be explored the mechanism of Ashitaba in managing NAFLD. We determined the impact of Ashitaba on NAFLD, particularly its underlying mechanisms at the bioinformatic level. The established NAFLD mouse model was treated with or without Ashitaba, and the underlying mechanism was explored using transcriptomics paired with metabolomics. Ashitaba reduced obesity and liver steatosis in NAFLD mice. It identified 429 differentially expressed genes (DEGs) and verified 45 differential metabolites, especially those that alleviate NAFLD via the FXR signaling pathway. Our data may provide insight into the therapeutic impact of Ashitaba in the management of NAFLD and may be useful in clinical interventions for NAFLD.<\/jats:p>","DOI":"10.3389\/fmed.2023.1247851","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T08:17:21Z","timestamp":1697617041000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Exploring the underlying mechanisms of Ashitaba in the management of non-alcoholic fatty liver disease by integrating the analysis of transcriptomics and metabolomics"],"prefix":"10.3389","volume":"10","author":[{"given":"Huan","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00018-018-2947-0","article-title":"Molecular pathways of nonalcoholic fatty liver disease development and progression","volume":"76","author":"Bessone","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"100346","DOI":"10.1016\/j.jhepr.2021.100346","article-title":"New targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3177\/jnsv.53.133","article-title":"Effects of dietary Angelica keiskei on serum and liver lipid profiles, and body fat accumulations in rats","volume":"53","author":"Nagata","year":"2007","journal-title":"J Nutr Sci Vitaminol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1021\/jf070720q","article-title":"Antidiabetic activities of chalcones isolated from a Japanese herb, Angelica keiskei","volume":"55","author":"Enoki","year":"2007","journal-title":"J Agric Food Chem"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1055\/s-0042-110496","article-title":"A review of the medicinal uses and pharmacology of Ashitaba","volume":"82","author":"Caesar","year":"2016","journal-title":"Planta Med"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/19390211.2018.1458366","article-title":"Ashitaba (Angelica keiskei) exudate prevents increases in plasminogen activator inhibitor-1 induced by obesity in Tsumura Suzuki obese diabetic mice","volume":"16","author":"Ohta","year":"2019","journal-title":"J Diet Suppl"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1055\/s-2006-960082","article-title":"Anti-tumor-promotion by principles obtained from Angelica keiskei","volume":"57","author":"Okuyama","year":"1991","journal-title":"Planta Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0304-3835(02)00018-6","article-title":"In vitro induction of the anticarcinogenic marker enzyme, quinone reductase, in human hepatoma cells by food extracts","volume":"180","author":"Hashimoto","year":"2002","journal-title":"Cancer Lett"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/nu11010204","article-title":"Simultaneous intake of Euglena gracilis and vegetables exerts synergistic anti-obesity and anti-inflammatory effects by modulating the gut microbiota in diet-induced obese mice","volume":"11","author":"Okouchi","year":"2019","journal-title":"Nutrients"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.foodchem.2013.12.026","article-title":"Quantitative analysis of phenolic metabolites from different parts of Angelica keiskei by HPLC-ESI MS\/MS and their xanthine oxidase inhibition","volume":"153","author":"Kim","year":"2014","journal-title":"Food Chem"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1021\/jf404175t","article-title":"Inhibitory effects of 4-hydroxyderricin and xanthoangelol on lipopolysaccharide-induced inflammatory responses in RAW264 macrophages","volume":"62","author":"Yasuda","year":"2014","journal-title":"J Agric Food Chem"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s12020-016-0861-5","article-title":"mTORC1 pathway mediates beta cell compensatory proliferation in 60% partial-pancreatectomy mice","volume":"53","author":"Li","year":"2016","journal-title":"Endocrine"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1016\/j.cmet.2021.06.012","article-title":"FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption","volume":"33","author":"Clifford","year":"2021","journal-title":"Cell Metab"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcmgh.2022.03.006","article-title":"Macrophage SCAP contributes to metaflammation and lean NAFLD by activating STING-NF-\u03baB signaling pathway","volume":"14","author":"Huang","year":"2022","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"970292","DOI":"10.3389\/fphys.2022.970292","article-title":"The AMPK pathway in fatty liver disease","volume":"13","author":"Fang","year":"2022","journal-title":"Front Physiol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/S2213-8587(18)30154-2","article-title":"Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies","volume":"7","author":"Stefan","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tips.2019.05.002","article-title":"Genetic insights for drug development in NAFLD","volume":"40","author":"Eslam","year":"2019","journal-title":"Trends Pharmacol Sci"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1053\/j.gastro.2020.01.051","article-title":"Therapeutic landscape for NAFLD in 2020","volume":"158","author":"Neuschwander-Tetri","year":"2020","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.fct.2014.12.021","article-title":"Toxicological assessment of Ashitaba Chalcone","volume":"77","author":"Maronpot","year":"2015","journal-title":"Food Chem Toxicol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jare.2021.06.001","article-title":"Hyperoside attenuates non-alcoholic fatty liver disease in rats via cholesterol metabolism and bile acid metabolism","volume":"34","author":"Wang","year":"2021","journal-title":"J Adv Res"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s13679-019-00345-1","article-title":"Nonalcoholic fatty liver disease and obesity treatment","volume":"8","author":"Brunner","year":"2019","journal-title":"Curr Obes Rep"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus\u2014mechanisms and treatments","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1039\/c4fo00525b","article-title":"Ashitaba (Angelica keiskei) extract prevents adiposity in high-fat diet-fed C57BL\/6 mice","volume":"6","author":"Zhang","year":"2015","journal-title":"Food Funct"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/metabo10040168","article-title":"Distinguishing NASH histological severity using a multiplatform metabolomics approach","volume":"10","author":"Ioannou","year":"2020","journal-title":"Metabolites"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"eaaz2841","DOI":"10.1126\/scitranslmed.aaz2841","article-title":"Glycine-based treatment ameliorates NAFLD by modulating fatty acid oxidation, glutathione synthesis, and the gut microbiome","volume":"12","author":"Rom","year":"2020","journal-title":"Sci Transl Med"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.3390\/ijms24021502","article-title":"Changes in lipidomics, metabolomics, and the gut microbiota in CDAA-induced NAFLD mice after polyene phosphatidylcholine treatment","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jhep.2019.10.003","article-title":"The gut-liver axis in liver disease: pathophysiological basis for therapy","volume":"72","author":"Albillos","year":"2020","journal-title":"J Hepatol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.freeradbiomed.2011.10.003","article-title":"Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis","volume":"52","author":"Rolo","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1126\/science.aay0542","article-title":"An AMPK-caspase-6 axis controls liver damage in nonalcoholic steatohepatitis","volume":"367","author":"Zhao","year":"2020","journal-title":"Science"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.apsb.2016.07.008","article-title":"Fatty liver diseases, bile acids, and FXR","volume":"6","author":"Zhu","year":"2016","journal-title":"Acta Pharm Sin B"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3389\/fendo.2014.00230","article-title":"O-GlcNAcylation links ChREBP and FXR to glucose-sensing","volume":"5","author":"Benhamed","year":"2014","journal-title":"Front Endocrinol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1172\/JCI65538","article-title":"Hepatic glucose sensing is required to preserve \u03b2 cell glucose competence","volume":"123","author":"Seyer","year":"2013","journal-title":"J Clin Invest"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"15338","DOI":"10.1096\/fj.202000836RR","article-title":"N-glycosylation of CREBH improves lipid metabolism and attenuates lipotoxicity in NAFLD by modulating PPAR\u03b1 and SCD-1","volume":"34","author":"Zhang","year":"2020","journal-title":"FASEB J"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1247851\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T08:17:24Z","timestamp":1697617044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1247851\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":41,"alternative-id":["10.3389\/fmed.2023.1247851"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1247851","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"article-number":"1247851"}}